Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Centessa Pharmaceuticals plc - American Depositary Shares (NQ:CNTA)

12.36 -0.15 (-1.24%)
Streaming Delayed Price Updated: 9:55 AM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Centessa Pharmaceuticals plc - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Warner Bros., Olo, Centessa, and PayPal and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Barclays, Warner Bros., Olo, and Centessa and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Centessa, PayPal, Opendoor, and Schmitt and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Analyst Ratings for Centessa Pharmaceuticals
  Within the last quarter, Centessa Pharmaceuticals (NASDAQ:CNTA) has observed the following analyst ratings: 
Via Benzinga
Bronstein, Gewirtz & Grossman, LLC, A Top Firm, Notifies Centessa Pharmaceuticals plc (CNTA) Investors of Class Action and Encourages Investors to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
NASDAQ:CNTA Shareholder Notice: Lawsuit Alleges Securities Laws Violations by Centessa Pharmaceuticals Plc
San Diego, CA -- (SBWIRE) -- 10/12/2022 -- An investor, who purchased shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA), filed a lawsuit against Centessa Pharmaceuticals plc over alleged Federal... 
Via SBWire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Centessa, PayPal, Opendoor, and Schmitt and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Centessa Culls Early-Stage Asset For Inherited Disorder
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Centessa and PayPal and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Centessa Pharmaceuticals Plc (NASDAQ:CNTA) Investor Alert: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 10/05/2022 -- An investigation on behalf of investors in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) was announced over potential breaches of fiduciary duties by... 
Via SBWire
INVESTOR NOTICE: Centessa Pharmaceuticals plc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – CNTA
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo and Centessa and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
CENTESSA PHARMACEUTICALS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Centessa Pharmaceuticals plc - CNTA
From Kahn Swick & Foti, LLC
Via Business Wire
Centessa Pharmaceuticals plc Shareholder Update: Robbins LLP Reminds Investors of Class Action Against Centessa Pharmaceuticals plc (CNTA)
From Robbins LLP
Via Business Wire
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
CENTESSA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Centessa Pharmaceuticals Plc and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
INVESTOR ALERT: Centessa Pharmaceuticals plc Investors with Substantial Losses Have Opportunity to Lead the Centessa Class Action Lawsuit - CNTA
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Centessa Pharmaceuticals plc (CNTA)
From Robbins LLP
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary
Via Benzinga
FDA Grants Orphan Drug Status To Centessa's Hemophilia B Candidate
Centessa Pharmaceuticals (NASDAQ: CNTA) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SerpinPC for the treatment of hemophilia B. A Phase 2a... 
Via Benzinga
Centessa Pharmaceuticals Plc (NASDAQ:CNTA) Shareholder Notice: Investigation over Potential Securities Laws Violations
San Diego, CA -- (SBWIRE) -- 08/23/2022 -- Centessa Pharmaceuticals plc is under investigation concerning possible securities laws violations in connection with certain financial statements. 
Via SBWire
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Morgan Stanley Downgrades Centessa Pharmaceuticals: Here's What You Need To Know
  Morgan Stanley downgraded its rating of Centessa Pharmaceuticals (NASDAQ:CNTA) to Underweight with a price target of $5.00, changing its price target from $10.00 to $5.00. Shares of Centessa... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2022
  
Via Benzinga
EQUITY ALERT: Rosen Law Firm Encourages Centessa Pharmaceuticals plc Investors with Losses in Excess of $100K to Inquire About Class Action Investigation – CNTA
From The Rosen Law Firm, P.A.
Via Business Wire
Goldman Sachs Maintains Neutral Rating for Centessa Pharmaceuticals: Here's What You Need To Know
  Goldman Sachs has decided to maintain its Neutral rating of Centessa Pharmaceuticals (NASDAQ:CNTA) and lower its price target from $5.00 to $4.00. Shares of Centessa Pharmaceuticals are trading down... 
Via Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Centessa Pharmaceuticals: Q2 Earnings Insights
  Centessa Pharmaceuticals (NASDAQ:CNTA) reported its Q2 earnings results on Wednesday, August 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.